Results 11 to 20 of about 30,408 (190)

Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia

International Journal of Mycobacteriology
Background: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used.
Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono   +5 more
doaj   +2 more sources

The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report

International Journal of Infectious Diseases, 2018
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis (MDR-TB) and end-stage renal disease (ESRD) may raise safety concerns. Currently, no clinical information is available on the use of bedaquiline to treat MDR-TB patients with ...
Seyeon Park, Kyu Min Lee, Insu Kim, Jeongha Mok   +3 more
doaj   +2 more sources

Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. [PDF]

PLoS ONE, 2019
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a novel mechanism of action in over 40 years, has already been detected in Mycobacterium tuberculosis. As a new drug, however, there is currently insufficient clinical
Malancha Karmakar, Carlos H M Rodrigues, Kathryn E Holt, Sarah J Dunstan, Justin Denholm, David B Ascher   +5 more
doaj   +3 more sources

High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia

Emerging Infectious Diseases
Bedaquiline is a cornerstone drug for treating drug-resistant tuberculosis. We analyzed 11 isolates from 9 patients who were treated with a bedaquiline-based regimen and remained culture-positive long after treatment start. In 4 of 8 resistant isolates,
Danila Zimenkov, Anastasia Ushtanit, Elizaveta Gordeeva, Elena Guselnikova, Yakov Schwartz, Natalia Stavitskaya   +5 more
doaj   +2 more sources

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia

Emerging Infectious Diseases
Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and ...
Gunar Günther, Lusia Mhuulu, Azaria Diergaardt, Viola Dreyer, Maria Moses, Kaarna Anyolo, Nunurai Ruswa, Mareli Claassens, Stefan Niemann, Emmanuel Nepolo   +9 more
doaj   +2 more sources

Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan

Microbiology Spectrum
Bedaquiline is a key drug recommended by the WHO for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant (XDR) TB, and its use could potentially shorten treatment duration with improved outcomes.
Faiqa Rashid, Shaukat Iqbal, Sabira Tahseen, Yanlin Zhao   +3 more
doaj   +2 more sources

Bedaquiline Resistance and Molecular Characterization of Rifampicin-Resistant Mycobacterium Tuberculosis Isolates in Zhejiang, China

Infection and Drug Resistance, 2023
Enyu Tong,1,* Ying Zhou,1,* Zhengwei Liu,2 Yelei Zhu,2 Mingwu Zhang,2 Kunyang Wu,2 Junhang Pan,2 Jianmin Jiang1– 3 1School of Public Health, Hangzhou Normal University, Hangzhou, 311100, People’s Republic of China; 2Tuberculosis Control ...
Tong E, Zhou Y, Liu Z, Zhu Y, Zhang M, Wu K, Pan J, Jiang J   +7 more
doaj   +1 more source

Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Scientific Reports
The treatment of multidrug-resistant tracheobronchial tuberculosis poses challenges, and research investigating the efficacy of bedaquiline or delamanid as treatment for this condition is limited.
Qing Chen, Tao Huang, Liping Zou, Xianzhen Tang, Zhengyu Shi, Xinwei Wang, Huaige Wu, Jiying Sun, Xiaoli Lu, Li Liang, Liangshuang Jiang, Dafeng Liu, Shenjie Tang, Guihui Wu, Wei He   +14 more
doaj   +2 more sources

Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria [PDF]

Nature Communications
Bedaquiline, an ATP synthase inhibitor, is the spearhead of transformative therapies against drug-resistant Mycobacterium tuberculosis. Here, we use remission spectroscopy to measure the energy-transducing cytochromes within unperturbed, respiring ...
Suzanna H. Harrison, Rowan C. Walters, Chen-Yi Cheung, Roger J. Springett, Gregory M. Cook, Morwan M. Osman, James N. Blaza   +6 more
doaj   +2 more sources

Successful Translational Prediction of Bedaquiline's Phase 2a Clinical Trial Results against Tuberculosis: The Zebrafish as a New Approach Methodology. [PDF]

Clin Pharmacol Ther
Tuberculosis remains an urgent global health crisis that requires an accelerated development of novel regimens. Rodent and rabbit studies currently inform early translational predictions. However, the zebrafish (Danio rerio) embryo/larva, as a New Approach Methodology, provides an ethical, cost‐effective, and high‐throughput non‐mammalian disease model
van Lieshout B, Hanuun A, van Hasselt JGC, van Wijk RC.   +3 more
europepmc   +2 more sources